References
- Sippl W, Jung M. Epigenetic targets in drug discovery. In: Methods and principles in medicinal chemistry. Vol. 42. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co., KGaA; 2009
- Supuran CT, Winum J-Y, eds. Drug design of zinc-enzyme inhibitors. Hoboken: John Wiley & Sons; 2009
- Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769–84
- Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007;5:981–9
- Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007;25:84–90
- Mai A, Altucci L. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int J Biochem Cell Biol 2009;41:199–213
- Martinet N, Bertrand P. Interpreting clinical assays for histone deacetylase inhibitors. Cancer Manage Res 2011;3:117–41
- Valente S, Conte M, Tardugno M, et al. Developing novel non-hydroxamate histone deacetylase inhibitors: the chelidamic warhead. Med Chem Comm 2012;3:298–304
- Butler KV, He R, McLaughlin K, et al. Stereoselective HDAC inhibition from cysteine-derived zinc-binding groups. Chem Med Chem 2009;4:1292–301
- Cole KE, Dowling DP, Boone MA, et al. Structural basis of the antiproliferative activity of largazole, a depsipeptide inhibitor of the histone deacetylases. J Am Chem Soc 2011;33:12474–7
- Suzuki T, Nagano Y, Matsuura A, et al. Novel histone deacetylase inhibitors: design, synthesis, enzyme inhibition, and binding mode study of SAHA-based non-hydroxamates. Bioorg Med Chem Lett 2003;13:4321–6
- Day JA, Cohen SM. Investigating the selectivity of metalloenzyme inhibitors. J Med Chem 2013;56:7997–8007
- Jacobsen JA, Fullagar JL, Miller MT, Cohen SM. Identifying chelators for metalloprotein inhibitors using a fragment-based approach. J Med Chem 2011;54:591–602
- Jacobsen FE, Breece RM, Myers WK, et al. Model complexes of cobalt-substituted matrix metalloproteinases: tools for inhibitor design. Inorg Chem 2006;45:7306–15
- Puerta DT, Lewis JA, Cohen SM. New beginnings for matrix metalloprotei-nase inhibitors: identification of high-affinity zinc-binding groups. J Am Chem Soc 2004;126:8388–9
- Trapencieris P, Strazdina J, Bertrand P. Synthesis of small and medium size monocyclic hydroxamic acids. Chem Heterocycl Comp (Engl. Ed.) 2012;48:833–55
- Borovika D, Bertrand P, Trapencieris P. Synthesis of macro-monocyclic hydroxamic acids. Chem Heterocycl Comp (Rus. Ed.) 2013;49:1685–705
- Spangler CW, McCoy RK. Preparation of conjugated aromatic polyenals by Wittig oxopropenylation. Synth Comm 1988;18:51–9
- Freeman AW, Urvoy M, Criswell ME. Triphenylphosphine-mediated reductive cyclization of 2-nitrobiphenyls: a practical and convenient synthesis of carbazoles. J Org Chem 2005;70:5014–19
- Molina P, Fresneda PM, Almendros P. Fused carbazoles by tandem aza Wittig/electrocyclic ring closure. Preparation of 6H-pyrido[4,3-b] carbazole, 11H-pyrido[4,3-a]carbazole and 11H-pyrido[3,4-a]carbazole derivatives. Tetrahedron 1993;49:1223–36
- Camp JE, Craig D, Funai K, White AJP. Decarboxylative Claisen rearrangement reactions: synthesis and reactivity of alkylidene-substituted indolines. Org Biomol Chem 2011;9:7904–12
- Finn PW, Bandara M, Butcher C, et al. Novel sulfonamide derivatives as inhibitors of histone deacetylase. Helv Chim Acta 2005;88:1630–57
- Ikuta H, Shirota H, Kobayashi S, et al. Synthesis and antiinflammatory activities of 3-(3,5-di-tert-butyl-4-hydroxybenzylidene)pyrrolidin-2-ones. J Med Chem 1987;30:1995–8
- Heinze-Krauss I, Angehrn P, et al. Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci. J Med Chem 1996;39:1864–71
- Li Y, Josowicz M, Tolbert LM. Diferrocenyl molecular wires. The role of heteroatom linkers. J Am Chem Soc 2010;132:10374–82